AVROBIO Inc. (AVRO) deprioritizing its Fabry disease program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Avrobio Inc. (AVRO) PT Lowered to $6 at Mizuho Securities
January 5, 2022 5:28 PM ESTMizuho Securities analyst Uy Ear lowered the price target on Avrobio Inc. (NASDAQ: AVRO) to $6.00 (from $28.00) while maintaining a Buy rating.
The analyst commented, "The new clinical data from the Fabry program is disappointing. We update our model to exclude our sales and... More
AVROBIO's (AVRO) Focus Shift is Disappointing, But Logical, Outlook is Cautions - Stifel
January 4, 2022 10:37 AM ESTStifel analyst Dae Gon Ha maintains a "Hold" rating on shares of AVROBIO Inc. (NASDAQ: AVRO), following news that company is shifting its portfolio... More
AVROBIO Inc. (AVRO) Halted, News Pending
January 4, 2022 6:55 AM ESTAVROBIO Inc. (NASDAQ: AVRO) Halted, News Pending
